Clinical Trial Update: Combined HAIC, Lenvatinib and Pucotenlimab As Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating a combination of hepatic arterial infusion chemotherapy (HAIC), lenvatinib, and pucotenlimab as conversion therapy for un…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• LENVIMA (lenvatinib)
• Pucotenlimab

Snippet

Sponsor: Tongji Hospital | Conditions: Cholangiocarcinoma Non-resectable | Phase 2 | Status: RECRUITING